Fluoro-2-deoxy-D-glucose (FDG)-PET in APOEepsilon4 carriers in the Australian population.
Apolipoprotein E-epsilon4 (APOEepsilon4) has been associated with increased risk of developing Alzheimer's disease (AD) and regional cerebral glucose hypometabolism, as measured by fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). We report here preliminary data from studies that aim to determine whether cerebral glucose hypometabolism is observed in APOEepsilon4 positive, cognitively intact individuals between the ages of 50 and 80, and whether there is an additional impact of subjective memory complainer (SMC) status on glucose metabolism determined by NeuroStat analysis. FDG-PET was conducted in 30 community dwelling, APOE-epsilon4 carriers without clinical evidence of dementia and objective cognitive impairment as assessed using a neuropsychological battery. Neurological soft-signs (NSS) were also assessed. Glucose hypometabolism was demonstrated in the anterior and posterior cingulate cortex and in the temporal association cortices in APOEepsilon4 carriers compared to the normative NeuroStat database. This pattern was particularly evident in APOEepsilon4 heterozygous individuals. SMC showed hypometabolism in the aforementioned brain regions, whereas non-SMC showed no significant pattern of glucose hypometabolism. FDG-PET with NeuroStat analysis showed that APOEepsilon4 carriers have mild glucose hypometabolism in areas associated with AD. SMC may be associated with AD-related differences in regional cerebral glucose metabolism. These findings are currently being investigated in a larger group of APOEepsilon4 carriers.
Rimajova
Mira
M
Centre of Excellence for Alzheimer's Disease Research and Care and School of Exercise Biomedical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia.
Lenzo
Nat P
NP
Wu
Jing-Shan
JS
Bates
Kristyn A
KA
Campbell
Andrew
A
Dhaliwal
Satvinder S
SS
McCarthy
Michael
M
Rodrigues
Mark
M
Paton
Athena
A
Rowe
Christopher
C
Foster
Jonathan K
JK
Martins
Ralph N
RN
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000235:genetics; D053327:Apolipoprotein E4 / Q000235:genetics*; D001315:Australia / Q000453:epidemiology; D002352:Carrier Proteins / Q000235:genetics*; D003430:Cross-Sectional Studies; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000453:epidemiology; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012307:Risk Factors
D053327:Apolipoprotein E4; D002352:Carrier Proteins; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18